Drug combo aims to shrink Hard-to-Treat sarcomas
NCT ID NCT04025931
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of two drugs—chidamide and toripalimab—in people with advanced soft-tissue sarcoma that has not responded to standard treatments. Chidamide is a pill that may help the immune system recognize cancer cells, while toripalimab is an immunotherapy given by IV. The study aims to see if this combination can shrink tumors or slow disease progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- chidamide and toripalimab
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced soft-tissue sarcoma who have run out of standard therapies.
- What could go wrong
- This is a relatively small, early-phase trial, so the results may not apply to all sarcoma types. The combination may cause side effects and may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-Sen Univerisity
Guangzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive antibody light up hidden tumors?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can engineered immune cells tackle childhood sarcoma?
- Can a Patient's own immune cells be engineered to fight a rare sarcoma?
- Can a Patient's own immune cells fight advanced sarcoma?
- Could a massive tissue bank unlock sarcoma's secrets?